Clinical Trials Logo

Triple Negative Breast Cancer clinical trials

View clinical trials related to Triple Negative Breast Cancer.

Filter by:
  • Not yet recruiting  
  • « Prev · Page 6

NCT ID: NCT04107142 Not yet recruiting - Prostate Cancer Clinical Trials

Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour

Start date: December 1, 2019
Phase: Phase 1
Study type: Interventional

This clinical trial is an open-label, single-centre, dose escalation, phase I study designed to investigate the safety and tolerability of Haploidentical / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted Gamma Delta (γδ) T Cells (CTM-N2D) in Subjects with Relapsed or Refractory Solid Tumour. The study objectives of this phase I study are to determine the safety, activity and the safe dose of haploidentical or allogeneic NKG2DL-targeting chimeric antigen receptor-grafted γδ T cells given four times weekly in patients with relapsed or refractory solid tumors of different types.

NCT ID: NCT03932526 Not yet recruiting - Clinical trials for Triple-negative Breast Cancer

Combined Use of Apatinib Mesylate and Vinorelbine Versus Single Use of Vinorelbine in Triple-negative Breast Cancer

Start date: June 24, 2019
Phase: Phase 2
Study type: Interventional

To compare the therapeutic effect of vinorelbine used alone or combined with apatinib mesylate for recurrent or metastatic TNBC patients who have at least received one chemotherapy regimen, including anthracyclines and taxanes, providing clinical evidence for multi-line treatment options for advanced TNBC.

NCT ID: NCT02802423 Not yet recruiting - Clinical trials for Triple Negative Breast Cancer

Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer.

Start date: November 1, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

The primary purpose of this study is to determine the safety and recommended dose level (RDL) of BLEX 404 Oral Liquid combined with Docetaxel monotherapy in a 21-day schedule. The secondary purpose is to assess the efficacy and safety of BLEX 404 Oral Liquid combined with Docetaxel monotherapy.

NCT ID: NCT02685657 Not yet recruiting - Clinical trials for Triple Negative Breast Cancer

Neoadjuvant Chemotherapy Docetaxel With or Without SELUMETINIB in Patients With Triple Negative Breast Cancer

Start date: September 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to increase survival of patients with early and locally advanced triple-negative breast cancer adding selumatinib to standard preoperative chemotherapy regimen.